Vincerx Pharma (VINC) 10-Q2024 Q1 Quarterly report

Filed: 14 May 24, 4:24pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: agent, andeach, ASUNo, ATM, beta, deducting, eligibleresearch, evolution, experimental, FASB, footing, incremental, instruction, instrumen, intervention, Januar, Leerink, lengthen, November, ofeach, optionsare, overhead, pharmacodynamic, prospective, retrospective, ts, underwriter, underwriting, underwritten, warrantat

Removed: abbreviated, accept, accretion, acute, adapt, adding, adequacy, adjusted, administered, Affordable, al, allegation, alleging, AML, amortization, ANDA, applying, area, assuming, assure, attack, Bruton, BTKi, California, called, CCPA, CDK, characterized, CLL, code, coding, cognizant, commonplace, competence, component, conform, connected, Continental, daily, delaying, Department, description, diffuse, disrupt, disrupted, DLBCL, dollar, double, duly, economy, Education, evolve, execute, executed, expanding, family, field, forecasted, GDPR, gene, geographic, impairment, imposing, inadvertently, injunctive, inspection, instrument, intent, intentional, interpreting, interruption, invent, inventor, investee, jeopardized, judged, June, legislative, leukemia, limitation, lymphocytic, lymphoma, managing, mantle, MCL, messenger, misleading, modal, mRNA, MYC, myelodysplastic, myeloid, patenting, performed, periodically, powering, prescribing, productivity, prosecuted, prosecutorial, quoted, reclassified, Reconciliation, registry, regulator, resale, restatement, RNA, Salzburg, Sciabacucchi, settlement, spread, statutory, studied, supplier, Switching, syndrome, tolerable, Transfer, transportation, Trust, tyrosine, undergone, updated, validate, vendor, withheld

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

VINC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Dr. Ahmed M. Hamdy, the Chief Executive Officer (Principal Executive Officer) of Vincerx Pharma, Inc. (the “Company”), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 14, 2024

/s/ Dr. Ahmed M. Hamdy

Dr. Ahmed M. Hamdy

Chief Executive Officer (Principal Executive Officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.